Folate receptor-targeted radionuclide therapy: preclinical investigation of anti-tumor effects and potential radionephropathy.

[1]  Eva Forssell-Aronsson,et al.  Evaluation of retinol binding protein 4 and carbamoylated haemoglobin as potential renal toxicity biomarkers in adult mice treated with 177Lu-octreotate , 2014, EJNMMI Research.

[2]  Josefine Reber,et al.  177Lu-EC0800 Combined with the Antifolate Pemetrexed: Preclinical Pilot Study of Folate Receptor Targeted Radionuclide Tumor Therapy , 2013, Molecular Cancer Therapeutics.

[3]  E. Christensen,et al.  Renal Uptake of 99mTc-Dimercaptosuccinic Acid Is Dependent on Normal Proximal Tubule Receptor–Mediated Endocytosis , 2013, The Journal of Nuclear Medicine.

[4]  R. Schibli,et al.  DOTA Conjugate with an Albumin-Binding Entity Enables the First Folic Acid–Targeted 177Lu-Radionuclide Tumor Therapy in Mice , 2013, The Journal of Nuclear Medicine.

[5]  Eva Forssell-Aronsson,et al.  Nephrotoxicity profiles and threshold dose values for [177Lu]-DOTATATE in nude mice. , 2012, Nuclear Medicine and Biology.

[6]  R. Schibli,et al.  Tumor targeting using 67Ga-DOTA-Bz-folate--investigations of methods to improve the tissue distribution of radiofolates. , 2011, Nuclear medicine and biology.

[7]  N. Obermüller,et al.  Biomarkers of kidney injury , 2011, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[8]  W. Oyen,et al.  Renal Toxicity of Radiolabeled Peptides and Antibody Fragments: Mechanisms, Impact on Radionuclide Therapy, and Strategies for Prevention , 2010, Journal of Nuclear Medicine.

[9]  R. Valkema,et al.  Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  François Jamar,et al.  Single photon emission-computed tomography (SPECT) for functional investigation of the proximal tubule in conscious mice. , 2010, American journal of physiology. Renal physiology.

[11]  P. Low,et al.  Folate-targeted therapeutic and imaging agents for cancer. , 2009, Current opinion in chemical biology.

[12]  Qianming Chen,et al.  Cell line cross-contamination: KB is not an oral squamous cell carcinoma cell line. , 2009, European journal of oral sciences.

[13]  Giovanni Paganelli,et al.  Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  Christof Baltes,et al.  A portable albumin binder from a DNA-encoded chemical library. , 2008, Angewandte Chemie.

[15]  J. Reddy,et al.  Comparative preclinical activity of the folate‐targeted Vinca alkaloid conjugates EC140 and EC145 , 2007, International journal of cancer.

[16]  F. Forrer,et al.  From outside to inside? Dose-dependent renal tubular damage after high-dose peptide receptor radionuclide therapy in rats measured with in vivo (99m)Tc-DMSA-SPECT and molecular imaging. , 2007, Cancer biotherapy & radiopharmaceuticals.

[17]  T. Visser,et al.  Long-term toxicity of [177Lu-DOTA0,Tyr3]octreotate in rats , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  Eva Forssell-Aronsson,et al.  Dosimetric characterization of radionuclides for systemic tumor therapy: influence of particle range, photon emission, and subcellular distribution. , 2006, Medical physics.

[19]  J. Hoppin,et al.  In vivo radionuclide uptake quantification using a multi-pinhole SPECT system to predict renal function in small animals , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  T. Visser,et al.  Localisation and mechanism of renal retention of radiolabelled somatostatin analogues , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  P. Low,et al.  Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. , 2005, Analytical biochemistry.

[22]  R. Finnell,et al.  Renal tubular reabsorption of folate mediated by folate binding protein 1. , 2005, Journal of the American Society of Nephrology : JASN.

[23]  H. V. van Boven,et al.  Inhomogeneous localization of radioactivity in the human kidney after injection of [(111)In-DTPA]octreotide. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  R. Wendt,et al.  Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  O. Delattre,et al.  Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide , 2002, Oncogene.

[26]  M. Mihatsch,et al.  A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[27]  P. Low,et al.  Indium-111-DTPA-folate as a potential folate-receptor-targeted radiopharmaceutical. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  A. Peters,et al.  Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue. , 1993, British Journal of Cancer.

[29]  E. Cohen,et al.  RADIATION NEPHROPATHY , 1976, The Lancet.

[30]  Philip S Low,et al.  Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. , 2008, Accounts of chemical research.

[31]  Marion de Jong,et al.  Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  L. Bostad,et al.  A high-affinity folate binding protein in proximal tubule cells of human kidney. , 1992, Kidney international.